- Over 80% disease-free survival without re-induction in BCG-unresponsive bladder cancer.
- 94% of patients preserved their bladder, avoiding radical surgery.
- High progression-free survival rate of 95.6% at 9 months.
Johnson & Johnson's (JNJ, Financial) innovative bladder cancer treatment, TAR-200—a gemcitabine-releasing system—has shown strong promise in early Phase 2b results from the SunRISe-1 study. More than 80% of patients maintained disease-free status without the need for reinduction, reflecting the potential efficacy of this novel approach.
Among the 52 patients enrolled in Cohort 4 of the study, notable findings include an 85.3% disease-free survival rate at six months and 81.1% at nine months. Critically, 94% of participants were able to avoid radical cystectomy, underscoring TAR-200's potential as a surgical alternative.
The study reported a progression-free survival rate of 95.6% at nine months. The treatment was generally well-tolerated, with most adverse effects being low-grade and resolving quickly. Notable side effects included dysuria (40.4%), pollakiuria (30.8%), and urinary urgency (26.9%).
These compelling results have catalyzed the continued evaluation of TAR-200 in the ongoing Phase 3 SunRISe-5 trial, which aims to compare its effectiveness against traditional chemotherapy in BCG-pretreated patients. If successful, TAR-200 could establish a new standard of care for high-risk non-muscle-invasive bladder cancer, offering patients a less invasive and effective treatment option.
Become a Premium Member to See This: (Free Trial):
